Verve Therapeutics (VERV)
(Delayed Data from NSDQ)
$6.31 USD
-0.42 (-6.24%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $6.31 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Price, Consensus and EPS Surprise
VERV 6.31 -0.42(-6.24%)
Will VERV be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VERV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VERV
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
VERV: What are Zacks experts saying now?
Zacks Private Portfolio Services
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More
Verve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls
Other News for VERV
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Commit To Purchase Verve Therapeutics At $5, Earn 27% Annualized Using Options
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q2 2024 Update
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Verve Therapeutics Expands Board with Two New Members